The Cold Open
BPC-157 is the biggest name in the recovery-peptide world. Joe Rogan mentions it. Athletes inject it. Physical therapy clinics stock it. Ask what the human trials say and the conversation gets quiet. This month: what the evidence actually looks like, where it ends, and why the gap between the hype and the data keeps widening.
Peptide of the Month: BPC-157
What it is. BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein found in human gastric juice. The "BPC" stands for Body Protection Compound, which tells you everything about the branding and not much about the science. In rats, it has been studied for decades in wound healing, tendon repair, ulcer protection, and neuroprotection. It appears to work by promoting blood vessel growth and nitric oxide signaling in injured tissue, though most of that evidence is preclinical.
What it's supposedly for. Gut healing, tendon and ligament repair, muscle recovery, and wound closure. In forums and clinics, it's pitched as a near-universal recovery accelerator.
The evidence as of today. Animal research is voluminous: dozens of papers, mostly from a single research group, showing promising results across multiple injury models. Human research is a very different story. A 2015 oral-tablet trial in healthy volunteers was posted on ClinicalTrials.gov and never published results. Two conference-abstract trials from 2003 and 2005 examined a rectal formulation for ulcerative colitis, but full peer-reviewed reports are not publicly available. A 2025 pilot study infused IV BPC-157 into two healthy adults and reported it was tolerated. That's the entire human record.
One thing to know: WADA has flagged it. The World Anti-Doping Agency classifies BPC-157 as a prohibited substance. Competitive athletes who test positive face sanctions.
Dozens of animal papers. Four human studies. Two of them are conference abstracts.
The catch. Not FDA-approved. Sold through research-chemical vendors where purity and identity vary vial to vial. The biggest gap is the one nobody talks about: the enormous preclinical literature has not translated into a single fully reported, peer-reviewed controlled human trial. A 2024 AP investigation into unapproved peptide injections flagged BPC-157 as one of the most common examples sold online.
Research Radar: What actually landed in 2024 and early 2025
Three BPC-157 updates worth knowing about.
The IV pilot (2025). The first published report of IV BPC-157 in humans: two healthy adults, doses up to 20 mg, no acute safety signals. So what: this is a two-person pilot, not a clinical trial. It answers "did anyone tip over," not whether it works.
The 2025 review paper. A major literature review catalogued the entire BPC-157 evidence base and concluded what careful readers already suspected: preclinical signals are strong, human trials are essentially absent, and claims outpace the data by a wide margin.
The AP report (November 2024). Mainstream press coverage of celebrity-endorsed peptide injections named BPC-157 as one of the most commonly sold unapproved products, and documented contamination and purity issues at grey-market suppliers.
The rule: If a peptide has thousands of animal citations and fewer than five published human studies, you are looking at a research program, not a clinical therapy.
Not medical advice. Most peptides discussed in this newsletter are investigational or research chemicals. Talk to a clinician before starting anything.